A randomized phase II, double-blind, multicenter study evaluating the efficacy and safety of autogene cevumeran plus nivolumab versus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma
A randomized phase II, double-blind, multicenter study evaluating the efficacy and safety of autogene cevumeran plus nivolumab versus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma
Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
BO45230
Codice EudraCT
2023-509023-40-00
Sponsor/Promotore
F. Hoffmann-La Roche Ltd
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator